Our data indicate that declined miR-106b levels could enhance osteoclast differentiation and bone resorption by targeting RANKL, TWIST and MMP2, which might partly explain the role of miR-106b down-regulation in GCT and bone metastasis. Here, TWIST1 is linked to granular cell tumor.